Bharat Parenterals' Q2 FY 2026-27 Quarterly Results

Result Summary

• Bharat Parenterals Ltd reported a 46.4% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Sep (Q2 FY 2026-27). On a year-on-year (YoY) basis, it witnessed a growth of 103.7%.
• Its expenses for the quarter were up by 29.6% QoQ and 65.4% YoY.
• The net profit decreased 432.0% QoQ and decreased 237.4% YoY.
• The earnings per share (EPS) of Bharat Parenterals Ltd stood at 17.15 during Q2 FY 2026-27.

Financial Statments for Q2 FY 2026-27

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Bharat Parenterals Ltd is a company that operates within the pharmaceutical industry. The company is primarily engaged in the manufacturing and marketing of pharmaceutical formulations and products. As a player in the pharma sector, Bharat Parenterals Ltd produces a range of medicinal products, which may include injectables, tablets, capsules, and other dosage forms. While specific recent developments or strategic initiatives undertaken by the company are not detailed in the provided data, it is typical for companies in this industry to focus on research and development, regulatory compliance, and market expansion efforts to stay competitive. However, further details about such activities or strategic plans are not available in the current dataset.

Revenue

In terms of revenue, Bharat Parenterals Ltd reported a total income of ₹138.82 crores in Q2FY27. This reflects a significant increase compared to the previous quarter (Q1FY27), which recorded a total income of ₹94.85 crores, marking a quarter-over-quarter (QoQ) growth of 46.4%. This upward trend is also evident when comparing the year-over-year (YoY) data, as the total income in Q2FY26 was ₹68.15 crores, indicating a substantial YoY growth of 103.7%. The consistent increase in total income over these periods may highlight the company's performance in revenue generation within the analyzed timeframe.

Profitability

Examining the profitability metrics, Bharat Parenterals Ltd experienced a notable improvement. The company reported a profit before tax (PBT) of ₹14.00 crores in Q2FY27, a recovery from a loss of ₹1.49 crores in Q1FY27, resulting in a QoQ change of -1039.6%. Similarly, on a YoY basis, the PBT improved from a loss of ₹7.31 crores in Q2FY26 to a profit in the current quarter, denoting a YoY change of -291.5%. After accounting for tax expenses of ₹2.18 crores in Q2FY27, the profit after tax (PAT) was ₹11.82 crores. This is a turnaround from a loss of ₹3.56 crores in Q1FY27 and a loss of ₹8.60 crores in Q2FY26, showing a QoQ change of -432.0% and a YoY change of -237.4%. Earnings per share (EPS) also rose to ₹17.15 from negative values in previous periods, indicating the company's return to profitability.

Operating Metrics

The financial data for Bharat Parenterals Ltd indicates that total expenses for Q2FY27 were ₹124.83 crores, compared to ₹96.34 crores in Q1FY27, reflecting a QoQ increase of 29.6%. Compared to Q2FY26, where total expenses were ₹75.46 crores, there was a YoY increase of 65.4%. The tax for Q2FY27 was ₹2.18 crores, slightly higher than the previous quarter, which was ₹2.07 crores, reflecting a QoQ increase of 5.3%, and a YoY increase from ₹1.29 crores in Q2FY26, marking a 69.0% rise. While specific financial ratios such as P/E or debt-to-equity ratios are not provided in the data, these expenses and tax changes contribute to understanding the financial dynamics and cost structure of the company during the periods analyzed. The shift in profitability metrics, alongside expenses, offers insight into the operational adjustments and financial health of the company over time.